Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in the US market. Already successful in Europe and Canada, HULIO provides an affordable, comparable alternative to the widely-used Humira (adalimumab). This landmark announcement comes shortly after Biocon Biologics’ $3.3 billion […]